Evaluating Heart Function in Patients with Pulmonary Arterial Hypertension
Evaluation of Right Ventricular Myocardial Work in Patients With Pulmonary Arterial Hypertension
This study is testing a new tool to see how well the right side of the heart is working in people with pulmonary arterial hypertension to help improve their treatment and care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | Central Hospital, Nancy, France Academic / other |
| Locations | 1 site (Nancy) |
| Trial ID | NCT06567379 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients diagnosed with pulmonary arterial hypertension (PAH) and aims to assess right ventricular (RV) function using a new noninvasive tool called myocardial work. The study will analyze RV myocardial work parameters in relation to one-year mortality risk, utilizing transthoracic echocardiography and right heart catheterization data collected at diagnosis and first reevaluation. By adapting techniques initially developed for the left ventricle, the study seeks to provide insights into RV performance under the specific conditions of PAH. The findings could help refine patient management and treatment strategies based on RV function.
Who should consider this trial
Good fit: Ideal candidates for this study are patients newly diagnosed with idiopathic, heritable, or drug-associated pulmonary arterial hypertension who have undergone specific heart evaluations.
Not a fit: Patients with pulmonary hypertension associated with left-heart disease, lung diseases, or other specific conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the assessment of heart function in PAH patients, potentially leading to better treatment outcomes and survival rates.
How similar studies have performed: While few studies have explored the use of myocardial work in right ventricular assessment, the approach is promising and has shown potential in other contexts, though its application in PAH is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All consecutive incident patients with a diagnosis of idiopathic, heritable, drug-associated PH, or associated with portal hypertension and referred to PH reference center in Nancy university hospital. * Transthoracic echocardiography (TTE) and a right heart catheterization (RHC) within 48 hours at diagnosis and at first reevaluation with PAH treatment Exclusion Criteria: * cardiac ultrasound data not analyzable (poor echogenicity or poor quality of RV slice). - -- Patients with PH associated with left-heart disease (group 2), PH associated with lung diseases and/or hypoxia (group 3), PH associated with pulmonary artery obstructions (group 4) and PH with unclear and/or multifactorial mechanisms (group 5) were also excluded. Patients with a positive response to the vasoreactivity test or with features of venous or capillaries involvement were also excluded.
Where this trial is running
Nancy
- Valentin — Nancy, France (Recruiting)
Study contacts
- Study coordinator: Simon Valentin, M.D.
- Email: s.valentin@chru-nancy.fr
- Phone: +33383153405
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.